Who owns Oric Pharmaceuticals, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ORIC from SEC Form 13F filings across 203 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 203 institutions disclosed 118.6M shares of Oric Pharmaceuticals, Inc. worth $1.59B — about 109.6% of shares outstanding; the largest disclosed holder is Nextech Invest Ltd.. Source: SEC Form 13F filings, parsed by EvidInvest.
203
13F holders
$1.59B
value, 2026 filers
109.6%
of shares outstanding (118.6M sh)
44
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ORIC's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Nextech Invest Ltd. | 7.2M | $96.5M | 4.3% | 6.6% | 0.0% |
| 2 | BlackRock, Inc. | 7.0M | $94.0M | 0.0% | 6.5% | +2.3% |
| 3 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.1M | $68.5M | 0.0% | 4.7% | -23.1% |
| 4 | AIHC Capital Management Ltd | 4.6M | $62.4M | 57.4% | 4.3% | +21.0% |
| 5 | SR ONE CAPITAL MANAGEMENT, LP | 4.6M | $62.2M | 5.4% | 4.3% | 0.0% |
| 6 | STATE STREET CORP | 4.1M | $55.6M | 0.0% | 3.8% | -15.7% |
| 7 | NEA Management Company, LLC | 4.1M | $55.5M | 4.1% | 3.8% | 0.0% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4.1M | $54.9M | 0.0% | 3.8% | +3.1% |
| 9 | VIKING GLOBAL INVESTORS LP | 3.6M | $48.0M | 0.1% | 3.3% | -30.5% |
| 10 | Column Group LLC | 3.5M | $47.7M | 38.4% | 3.3% | 0.0% |
| 11 | Siren, L.L.C. | 3.4M | $45.2M | 1.1% | 3.1% | +12.0% |
| 12 | ALKEON CAPITAL MANAGEMENT LLC | 3.2M | $43.6M | 0.1% | 3% | -13.4% |
| 13 | EcoR1 Capital, LLC | 3.0M | $40.8M | 1.8% | 2.8% | -55.0% |
| 14 | Venrock Adviser, LLC | 2.9M | $39.7M | 1.9% | 2.7% | -31.8% |
| 15 | FMR LLC | 2.6M | $35.5M | 0.0% | 2.4% | -0.1% |
| 16 | D. E. Shaw & Co., Inc. | 2.5M | $33.1M | 0.0% | 2.3% | +55.3% |
| 17 | Defilade Capital Management, L.P. | 2.3M | $30.6M | 5.1% | 2.1% | +116.9% |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 2.2M | $29.6M | 0.0% | 2% | +5.0% |
| 19 | CITADEL ADVISORS LLC | 2.1M | $28.4M | 0.0% | 2% | -18.6% |
| 20 | MORGAN STANLEY | 2.0M | $27.4M | 0.0% | 1.9% | +13.5% |
| 21 | DIMENSIONAL FUND ADVISORS LP | 1.9M | $25.6M | 0.0% | 1.8% | +5.5% |
| 22 | FRANKLIN TEMPLETON INC | 1.9M | $17.6M | 0.0% | 1.7% | +4.9% |
| 23 | MPM BIOIMPACT LLC | 1.8M | $24.5M | 1.8% | 1.7% | -3.2% |
| 24 | GOLDMAN SACHS GROUP INC | 1.8M | $24.3M | 0.0% | 1.7% | -26.5% |
| 25 | Integral Health Asset Management, LLC | 1.7M | $20.2M | 1.2% | 1.6% | -10.5% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.